- 27 September
-
On September 26, 2024, TASS hosted an expert discussion in the format of a federal teleconference Moscow-St. Petersburg-Ekaterinburg-Novosibirsk-Vologda-Anapa, dedicated to discussing the role, reasons and mechanisms for stimulating In Ekaterinburg, Alexander Petrov, the Chairman of the Board of Directors of Medsintez Plant LLC, told the participants about Triazavirin, an innovative domestic antiviral drug, as a success case of private investment in science.
- 07 September
-
60 leading Russian reproductologists visited the pharmaceutical company Medsintez Plant in Novouralsk on September 4, 2024. This event was timed to coincide with the celebration of the 3rd anniversary of the opening of the production workshop for biotechnological substances for the reproductive health of women, as well as the Annual International Conference «Reproductive Technologies Today and Tomorrow» in Ekaterinburg. Leading experts and conference speakers visited the production of the first Russian follitropin alpha for the treatment of human infertility, Primapur®.
- 02 August
-
In 2024, the Medsintez Plant in collaboration with Tonghua Anrate Biopharmaceutical Co. launched the production of the substance and finished dosage forms of the world's first registered drug of recombinant human albumin. The drug was obtained using Pichia Pastoris cells by the recombinant DNA technology.
- 11 July
-
The Medsintez Plant has participated in an international business meeting with the delegation from the United Arab Emirates as part of the INNOPROM 2024 business program in Ekaterinburg. The meeting with representatives of the national Ministry of Industry, pharmaceutical and medical industries of the UAE was organized by the Ministry of Industry and Trade of the Russian Federation. The meeting was attended by the Deputy Minister of Industry and Advanced Technology of the UAE, representatives of Globalpharma, SayGen, Hayat Biotech, Abu Dhabi Medical Devices.
- Home
- Cluster members
- Ural Biomedical Company LLC
Ural Biomedical Company LLC
Genetic and gene and cell technologies (GCT), which make it possible to modify the properties of cells in a targeted manner, is a direction that the UN has officially recognized as a technology of the 21st century.
Hopes for the treatment of the most severe and massive diseases, such as cardiovascular, oncological and metabolic diseases, are associated with success in the development of GCT.
The small innovative enterprise Ural Biomedical Company LLC acts as a coordinator in this area, bringing together the efforts of specialists from the Department of Molecular and Cellular Technologies of the Ural State Medical University and the Laboratory of Cell and Gene Therapy Technology of the Institute of Medical Cellular Technologies in conducting an R&D cycle and implementing innovative projects for the development, production and use of a new generation of personalized medicines based on gene and gene-cell technologies based on the patented developments of one of the leading scientific schools in Russia – Professor O. G. Makeev's School.
Currently, the studies coordinated by Ural Biomedical Company LLC are at different stages of preclinical and clinical trials, which are highly recognized both in Russia and abroad – in particular, representatives of the above scientific school have obtained dozens of patents, have been awarded gold medals at European and Russian forums and exhibitions of biomedical technologies.
According to the National Society of Regenerative Medicine, a unique product for the Russian and world markets – AversGel – a gel for natural skin rejuvenation based on components of a certified human stem cell line, entered the top 10 breakthrough technologies in Russia in 2017 with the comment: "These technologies will remain with us for a long time. They will change the economy and politics, make a breakthrough in medicine, leave a cultural mark. Some of them are just taking shape, while others can take more than a decade to develop. But you need to know about them right now.”
